Our mission is to transform the discovery and development of therapeutic monoclonal antibodies.
Nottingham University Therapeutic Antibody Centre
Nottingham University Therapeutic Antibody Centre (NUTAC) is dedicated to producing novel therapeutic monoclonal antibodies (mAbs) for the treatment of cancer and infectious disease. It is a newly established unit, based on Professor Lindy Durrant’s track record for delivering innovative immunotherapeutic products to the clinic. Lindy Durrant is a Professor in Cancer Immunotherapy at the University and the CEO of Scancell Limited, the University spin-out company she established in 1997.
The mAb group at NUTAC have recently developed a technology to unlock the glycome to allow for the production of anti-glycan mAbs. This has the potential to identify numerous new targets typically missed in conventional screening strategies. Our ability to unlock the glycome presents a unique proposition for the diagnosis, treatment and prevention of disease.
Attending BIO 22-25 April
NUTAC will be attending the 2013 BIO International Convention from the 22-25 April at McCormick Place, Chicago, Illinois.